Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies - Wikidata - wikimedia - TriplyDB

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

http://www.wikidata.org/entity/Q33795160

about

Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders.Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.

P2860

Q36928725-449FE553-89E8-4061-AFEA-081C99A76803 Q37212916-9805D354-83FD-4B48-85C4-C402886FC780

P2860

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

http://www.wikidata.org/entity/Q33795160

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

@ast

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

@en

type

label

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

@ast

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

@en

prefLabel

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

@ast

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

@en

P1433

Q33795160-264ED7FF-11ED-4BEB-83F8-1EEE91BF6061

P1476

Q33795160-8FA9F5BC-3645-4526-A5BA-817D4FE334BD

P2093

Q33795160-7D0D2787-BAB9-4D4D-9767-ADCCE7597A9C

Q33795160-7D8DBD00-6D27-46A7-8DE2-464544DE950E

Q33795160-83908F0E-C5BD-4779-BE93-C9CF7F66CFBF

Q33795160-8E492B14-8B1A-4D93-9B4E-DFDFDADF0AD1

Q33795160-9D6E0222-FB8B-415A-9F20-1F16837F42C2

Q33795160-A587E469-49FD-4790-BE4D-E895813E68C9

Q33795160-A5D0F697-638F-49E5-969F-A71388D021C7

Q33795160-B8FA31A0-8ED5-402C-B593-87885E9D37BC

Q33795160-BAC2BFA8-C3CC-4955-83EA-5D5F8BEA5921

Q33795160-BC88E347-3EF1-4031-B0AE-1A207D1DB0FA

P2860

Q33795160-07A82A2D-A3CC-4DDD-9EB8-299FC8B01FD3

Q33795160-07FE7937-18A4-48B3-A272-3AC0742BE15D

Q33795160-0B83D4D0-9463-445D-927A-C61C6D8AFA90

Q33795160-1865AA7D-CB78-4875-A50D-8561CE2CAC98

Q33795160-3302E801-CA1A-403C-AB6D-0ED958310722

Q33795160-35ABA872-D87E-4F0D-BE91-510D284055EC

Q33795160-3B1AAD52-16BC-487B-A5FA-55D35BDA81B1

Q33795160-6DD56EAA-8EE8-4876-8782-D7DB57992EF6

Q33795160-7860ABFC-811C-4AD3-A832-CDBA50E688DA

Q33795160-8F541B6E-57D9-40C3-A59A-F622015C0408

P304

Q33795160-4AB03319-76A7-4F21-92BE-E5CB77FE8AFE

P31

Q33795160-8A50267F-6F1D-4163-ABC9-A8EA0720DEDF

P356

Q33795160-03AD2055-DA6E-42D5-83B9-7A7A8BEF3E37

P433

Q33795160-F59C2083-4B2A-4F4A-B09F-62CD3F670B76

P478

Q33795160-1713D891-A703-45A1-B48E-7DD8EABB0F2C

P577

Q33795160-81DB956D-92AA-4A69-A150-754F2DF368D4

P698

Q33795160-7190CB04-EBEE-416B-BDDE-CF95ED2BDFC4

P932

Q33795160-340D089E-5A12-46D5-AD18-B036E79BA860

P356

J.EXPHEM.2012.01.014

P1433

Experimental Hematology

P1476

Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies

@en

P2093

Adetola Kassim

http://www.w3.org/2001/XMLSchema#string

Bipin N Savani

http://www.w3.org/2001/XMLSchema#string

Brian Engelhardt

http://www.w3.org/2001/XMLSchema#string

David Morgan

http://www.w3.org/2001/XMLSchema#string

John P Greer

http://www.w3.org/2001/XMLSchema#string

Madan Jagasia

http://www.w3.org/2001/XMLSchema#string

Nishitha Reddy

http://www.w3.org/2001/XMLSchema#string

Stacey Goodman

http://www.w3.org/2001/XMLSchema#string

Stephen J Brandt

http://www.w3.org/2001/XMLSchema#string

Wichai Chinratanalab

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of chronic graft-versus-host disease in 2011

Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.

Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents.

P304

431-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EXPHEM.2012.01.014

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22269114

http://www.w3.org/2001/XMLSchema#string

P932

4067702

http://www.w3.org/2001/XMLSchema#string